Perceval Sutureless valve is now embarked on 1200 pt worldwide study to compare it with standard sutured valve
Sorin
FDA Approval for Perceval Sutureless Heart Valve
Major milestone as patients needing open aortic valve replacement benefit from easier-to-implant prosthesis
New Trial Will Compare Perceval Sutureless Valve to Standard Bioprostheses
Sorin’s newly announced study is first international prospective RCT to compare its TAVR offering with traditional replacement valve
New Clinical Trial with World’s First Triple-Site Ventricular (Tri-V) Pacing CRT-D Device
Study will evaluate whether response to cardiac resynchronization therapy (CRT) may be improved in selected heart failure patients through Tri-V pacing.
U.S. Next? Sorin Gains Health Canada Approval for Perceval Valve
Sorin’s Sutureless Valve is in the process of undergoing U.S. FDA approval, but in the meantime is beefing up its international presence with the go-ahed in another market
EU Launch of Sorin’s REPLY CRT-P, World’s Smallest Cardiac Resynchronization Pacemaker
Tiny device offers patient benefit of minimal size combined with functionality including sleep apnea monitoring
New U.S. Clinical Support for Sorin’s Solo Smart Pericardial Aortic Valve
Solo Smart offers the superior hemodynamics of a stentless valve combined with a stented valve’s ease of implantation
Sorin Enjoys Positive AATS Perceval Valve Presentations
Sorin’s sutureless aortic valve demonstrates improved outcome compared with TAVR in medium-high risk patients and favorable outcomes in every day surgery
Japanese Regulatory Approval for Sorin’s MRI Compatible Pacing System
Sorin Group has gained Japanese regulatory approval for its new KORA 100 pacing system with automatic magnetic resonance imaging mode
FDA Clearance and First U.S. Implant of Sorin’s Memo 3D ReChord Annuloplasty Ring
Sorin has gained U.S. FDA clearance for Memo 3D ReChord™, an innovative semi-rigid annuloplasty ring for mitral valve repair.
Sorin’s RESPOND CRT IDE Clinical Trial Completes Enrollment
Can CRT optimization using SonR heart sensor improve outcome in heart failure patients? A significant study, now fully enrolled, should tell us.
CE Mark and First Implant of Sorin’s MEMO 3D ReChord™
Sorin Group has gained CE mark certification for its new MEMO 3D ReChord™ mitral valve annuloplasty ring, which it is making immediately available in Europe.
Sorin to Explore Sleep Apnea Opportunity with Respicardia Deal
Sorin Group has announced that it is to make a $20 million minority investment in Respicardia, a developer of implantable therapies to improve Respiratory Rhythm Management™.
Study Shows 95.5% 3 Year Freedom from Valve-Related Death with Sorin’s Freedom Solo
Sorin Group is touting the results of the European and North American (Canada and US) cohort study on the Freedom Solo valve.
Trials and Economics Support Sorin’s Perceval Sutureless Valve
Sorin Group has announced the results of the Perceval CAVALIER Trial and of the Pooled European Multicenter Experience at this week’s 28th EACTS Congress
First U.S. Implant of Sorin’s Solo Smart Stentless Valve
The first U.S. implantation of Sorin’s Solo Smart aortic valve represents a first removable stent valve procedure in the country.